Wall Street analysts expect that Apellis Pharmaceuticals Inc (NASDAQ:APLS) will announce earnings per share (EPS) of ($0.63) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Apellis Pharmaceuticals’ earnings. The business is scheduled to issue its next quarterly earnings results on Tuesday, October 30th.
According to Zacks, analysts expect that Apellis Pharmaceuticals will report full year earnings of ($2.20) per share for the current year, with EPS estimates ranging from ($2.42) to ($1.85). For the next year, analysts anticipate that the firm will post earnings of ($2.68) per share, with EPS estimates ranging from ($3.24) to ($1.97). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Apellis Pharmaceuticals.
Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, July 31st. The company reported ($0.61) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.14).
Shares of APLS stock traded down $0.52 during mid-day trading on Thursday, reaching $18.51. 241,666 shares of the stock traded hands, compared to its average volume of 277,227. Apellis Pharmaceuticals has a 1-year low of $12.45 and a 1-year high of $32.00. The firm has a market capitalization of $1.12 billion and a price-to-earnings ratio of -5.28. The company has a current ratio of 26.02, a quick ratio of 26.02 and a debt-to-equity ratio of 0.12.
In related news, major shareholder Morningside Venture Investment acquired 81,323 shares of the business’s stock in a transaction that occurred on Friday, September 21st. The shares were bought at an average cost of $19.48 per share, with a total value of $1,584,172.04. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel David O. Watson sold 15,776 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Friday, September 14th. The stock was sold at an average price of $18.78, for a total value of $296,273.28. The disclosure for this sale can be found here. Company insiders own 9.30% of the company’s stock.
Several institutional investors have recently bought and sold shares of APLS. venBio Partners L.P. acquired a new position in shares of Apellis Pharmaceuticals in the second quarter worth approximately $72,482,000. Hillhouse Capital Management Ltd. lifted its stake in shares of Apellis Pharmaceuticals by 203.0% in the second quarter. Hillhouse Capital Management Ltd. now owns 4,328,289 shares of the company’s stock worth $95,222,000 after acquiring an additional 2,899,718 shares during the period. BlackRock Inc. lifted its stake in shares of Apellis Pharmaceuticals by 152.9% in the second quarter. BlackRock Inc. now owns 2,798,968 shares of the company’s stock worth $61,578,000 after acquiring an additional 1,692,121 shares during the period. Sofinnova Ventures Inc acquired a new position in shares of Apellis Pharmaceuticals in the first quarter worth approximately $20,159,000. Finally, Millennium Management LLC acquired a new position in shares of Apellis Pharmaceuticals in the second quarter worth approximately $19,656,000. 57.58% of the stock is currently owned by institutional investors.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.
Featured Article: Index Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.